Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BB Biotech AGXSWX:BION -0.72%32 Price-to-Tangible-Book is 0.99 as of Sep. 02, 2026. GuruFocus rates XSWX:BION with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 1,133 Biotechnology companies, BB Biotech AG ranks better than 87.73% on this metric.
The historical rank and industry rank for BB Biotech AG's Price-to-Tangible-Book or its related term are showing as below:
XSWX:BION'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.85 Med: 1.02 Max: 1.3
Current: 0.99
During the past 13 years, BB Biotech AG's highest Price to Tangible Book Ratio was 1.30. The lowest was 0.85. And the median was 1.02.
XSWX:BION's Price-to-Tangible-Book is ranked better than 87.73% of 1133
companies
in the Biotechnology industry
Industry Median: 3.26
vs XSWX:BION: 0.99
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
BB Biotech AG Price-to-Tangible-Book Related Terms
BB Biotech AG Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for BB Biotech AG's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BION vs VRTX, REGN, MRNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, BB Biotech AG's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
BB Biotech AG (XSWX:BION) has a Price-to-Tangible-Book of 0.99 as of Sep. 02, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on BB Biotech AG and its competitors. According to the industry distribution chart, BB Biotech AG ranks #139 out of 1133 companies in the Biotechnology industry, placing it in the top 12.3%.
Is BB Biotech AG's Price-to-Tangible-Book too high?
BB Biotech AG's current Price-to-Tangible-Book is 0.99. The Biotechnology industry median Price-to-Tangible-Book is 3.26. BB Biotech AG's value of 0.99 is 69.6% below this industry median. Based on the distribution chart, BB Biotech AG ranks #139 out of 1133 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BB Biotech AG has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BB Biotech AG ranks #139 out of 1133 companies for Price-to-Tangible-Book. This places BB Biotech AG in the top 12% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 3.26. BB Biotech AG's value of 0.99 is 69.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.26, based on 1,133 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BB Biotech AG's current Price-to-Tangible-Book of 0.99 is 69.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on BB Biotech AG and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BB Biotech AG's current Price-to-Tangible-Book is 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current Price-to-Tangible-Book of 0.99. The current Price-to-Tangible-Book is 0.99 and 69.6% below the Biotechnology industry median of 3.26. BB Biotech AG's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current Price-to-Tangible-Book is 0.99 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
32GF Score
Get the complete analysis for XSWX:BION
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BION has been successfully added to your 
